Business
"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for Injection
"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for Injection
About this update from Tasly Pharmaceutical Group Co. Ltd. Class A
Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for InjectionThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference:View Attachment
View stock analysis, news, and events for Tasly Pharmaceutical Group Co. Ltd. Class A